Ignite Creation Date:
2024-05-06 @ 4:20 PM
Last Modification Date:
2024-10-26 @ 2:08 PM
Study NCT ID:
NCT04950439
Status:
RECRUITING
Last Update Posted:
2023-09-06
First Post:
2021-06-29
Brief Title:
Pyrophosphate and Arterial Calcification in Chronic Kidney Disease
Sponsor:
Centre Hospitalier Universitaire de Nice
Organization:
Centre Hospitalier Universitaire de Nice
Study Overview
Official Title:
Pyrophosphate a New Biomarker to Predict Arterial Calcification in Chronic Kidney Disease
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Predical
Brief Summary:
Arterial calcifications start at early stages of chronic kidney disease CKD and are associated to cardiovascular mortality Pyrophosphate PPi is an endogenous compound which stops the mineralization process in bones and is expected to act at ectopic sites In uremic rats low PPi plasma levels are associated with high calcium content in the aorta and peritoneal administration of PPi blocks this process People on maintenance dialysis or kidney transplant recipients have low plasma levels of PPi and show high scores of arterial calcification The purpose is to determine the role of low PPi in the development of arterial calcifications in patients with CKD stage 3 or 4 To that aim 252 patients with eGFR between 59 et 20 mlmin173 m2 will be recruited and will be examined at baseline and three years later
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None